Please try another search
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Jean-Francois Formela | 65 | 2016 | Independent Director |
Josep Tabernero | - | 2020 | Member of Scientific Advisory Board |
Kevan M. Shokat | - | 2020 | Member of Scientific Advisory Board |
Iain D. Dukes | 64 | 2016 | Independent Director |
George Daniel Demetri | 65 | 2020 | Chair of Scientific Advisory Board |
David Bonita | 46 | 2016 | Independent Director |
Otello Stampacchia | 48 | 2020 | Independent Director |
Maria Koehler | 65 | 2021 | Independent Director |
Richard Wooster | 57 | 2022 | Independent Director |
Neal Rosen | 72 | - | Member of Scientific Advisory Board |
Owen P. Hughes | 48 | 2023 | Chairman of the Board |
Mark Manfredi | 51 | 2017 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review